Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 6/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.37 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23969503 | 0.88 | KMT2A (0.42) | HIF1AMEN1KMT2APPARGPPARA | |
| SCHEMBL25552199 | 0.87 | HIF1A (0.48) | HIF1ANPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL23977993 | 0.85 | HIF1A (0.41) | HIF1ANPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL23971878 | 0.84 | HIF1A (0.54) | HIF1ANPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL23971691 | 0.83 | S1PR1 (0.34) | HIF1ASMN1; SMN2 | |
| SCHEMBL25551838 | 0.83 | KCNK3 (0.38) | NPC1RAB9AKCNK3KCNK9LMNA | |
| SCHEMBL25600089 | 0.82 | S1PR1 (0.31) | SMN1; SMN2 | |
| SCHEMBL25720601 | 0.81 | HIF1A (0.32) | HIF1ANPC1RAB9AL3MBTL1SMN1; SMN2 | |
| SCHEMBL31711599 | 0.81 | NPC1 (0.36) | HIF1ANPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL31711609 | 0.81 | NPC1 (0.36) | HIF1ANPC1RAB9AKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172207-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS I | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230172204-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS III | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
| US-20230172205-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS IV | BASF SE (DE) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230172204-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS III | COX5B, SQOR, UQCRB | HIF1A 2044/4885NPC1 1501/4885RAB9A 401/4885 |
| US-20230172207-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS I | COX5B, SQOR, UQCRB | HIF1A 1889/4885NPC1 1332/4885RAB9A 439/4885 |
| US-20230172205-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS IV | COX5B, SQOR, COX5A | HIF1A 2001/4885NPC1 1456/4885RAB9A 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.